Marvel Biosciences Corp. Retains Virtus Advisory Group To Provide Corporate Communications Services
2021-08-03 17:38 ET - News Release Mr. J. Roderick (Rod) Matheson reports MARVEL BIOSCIENCES CORP. RETAINS VIRTUS ADVISORY GROUP TO PROVIDE CORPORATE COMMUNICATIONS SERVICES Marvel Biosciences Corp. has retained Virtus Advisory Group Inc. to develop and implement a strategic corporate communications program to increase the company's exposure among industry stakeholders and investors across...
Marvel Biosciences Corp. To Commence CGMP Manufacturing Of Its Lead Asset MB-204
2021-07-21 12:37 ET - News Release Dr. Mark Williams reports MARVEL BIOSCIENCES CORP. TO COMMENCE CGMP MANUFACTURING OF ITS LEAD ASSET MB-204 Marvel Biosciences Corp.'s wholly owned subsidiary Marvel Biotechnology Inc. has achieved a significant science milestone in the development of its lead compound MB-204. Marvel Biotechnology has entered into a current good manufacturing process (cGMP)...
Alphanco Venture Corp. Changes Name To Marvel Biosciences Corp. And Completes Acquisition Of Marvel Biotechnology Inc.
Alphanco receives conditional OK for Marvel acquisition
2021-03-18 16:43 ET - News Release Ms. Joanne Yan reports ALPHANCO VENTURE CORP. ANNOUNCES CONDITIONAL APPROVAL FOR ITS ACQUISITION OF MARVEL BIOTECHNOLOGY INC. Alphanco Venture Corp. has received conditional approval from the TSX Venture Exchange for its acquisition of all of the outstanding shares of Marvel Biotechnology Inc. as its proposed qualifying transaction as defined under TSX-V...
Alphanco to acquire Calgary biotech company as QT
2020-11-03 10:57 ET - News Release Mr. Roderick Matheson reports ALPHANCO VENTURE CORP. TO ACQUIRE MARVEL BIOTECHNOLOGY INC. IN A REVERSE TAKEOVER TRANSACTION Alphanco Venture Corp. has signed a merger agreement dated Oct. 28, 2020, pursuant to which the company will acquire all of the outstanding shares of Marvel Biotechnology Inc. The proposed transaction is intended to be a qualifying...